Lymphoma

Lymphoma is a group of blood cancers that develop in the lymphatic system—the network of vessels, nodes, and organs that help fight infections and filter waste from the body. Approximately 620,000 new cases are diagnosed worldwide each year. The disease occurs when lymphocytes (a type of white blood cell) undergo genetic mutations that cause them to grow and divide uncontrollably, accumulating in lymph nodes, spleen, bone marrow, and sometimes other organs. Lymphomas are broadly divided into two main categories: Hodgkin lymphoma (about 10-15% of cases) and non-Hodgkin lymphoma (NHL), which encompasses over 60 distinct subtypes with very different behaviors and treatment responses. The most common NHL subtypes include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and mantle cell lymphoma. Some lymphomas grow slowly over years (indolent), while others progress rapidly (aggressive). Most lymphomas originate from B cells, though some arise from T cells or natural killer cells. The exact causes aren't fully understood, but factors including immune system dysfunction, certain infections (Epstein-Barr virus, H. pylori), autoimmune diseases, and some genetic conditions increase risk. Common symptoms include painless swelling of lymph nodes, fever, night sweats, unexplained weight loss, and fatigue, though some slow-growing types cause no symptoms for years.

Treatment varies dramatically depending on lymphoma type and stage. Many indolent lymphomas are monitored without immediate treatment (watch-and-wait approach) since therapy doesn't necessarily extend survival and can cause side effects, with treatment starting when disease becomes symptomatic. When treatment is needed, the standard often combines chemotherapy with rituximab, an antibody that targets CD20 protein on lymphoma cells—this combination (R-CHOP for aggressive lymphomas) transformed outcomes when introduced in the 1990s. Hodgkin lymphoma is highly curable even at advanced stages using combination chemotherapy regimens, with cure rates exceeding 80-90% depending on stage and subtype. For aggressive lymphomas, intensive chemotherapy is standard, sometimes followed by stem cell transplant for high-risk patients or those whose disease relapses. Radiation therapy is used for localized disease or specific situations. CAR-T cell therapy—where patients' immune cells are engineered to attack lymphoma—has been approved for certain relapsed DLBCL and follicular lymphoma, offering durable remissions for many who had exhausted other options. Targeted therapies including BTK inhibitors (like ibrutinib) have transformed treatment for certain subtypes including mantle cell lymphoma and marginal zone lymphoma. Newer antibody-drug conjugates like brentuximab vedotin are standard for some T-cell lymphomas and Hodgkin lymphoma. Treatment intensity varies from single-agent oral therapy for indolent types to months of intensive chemotherapy for aggressive forms.

Relapsed or refractory disease—when lymphoma returns after treatment or doesn't respond initially—remains challenging, particularly for patients who have already tried multiple therapies and aren't candidates for CAR-T or stem cell transplant. Certain aggressive subtypes including primary mediastinal B-cell lymphoma, some T-cell lymphomas, and lymphomas with specific high-risk genetic features have poorer outcomes than more common types and need better treatment options. CAR-T therapy, while transformative for many, isn't universally effective, with some patients not responding and others relapsing months or years later; the treatment also carries risks of serious side effects including cytokine release syndrome and neurological toxicity that require specialized management. The manufacturing process for CAR-T takes weeks, creating delays that can be problematic for rapidly growing lymphomas. Treatment toxicity remains significant—chemotherapy regimens can cause nerve damage, heart problems, and secondary cancers years later, particularly affecting younger patients who have decades of life ahead. Better biomarkers to predict which indolent lymphomas will transform into aggressive types would help identify patients needing closer monitoring or earlier intervention. Some patients experience long-term effects from treatments including fatigue, cognitive changes, and increased infection risk that affect quality of life years after achieving remission.

Bispecific antibodies that simultaneously bind lymphoma cells and T cells are showing remarkable results in Phase 2 and Phase 3 trials, with several already approved for relapsed DLBCL and others advancing rapidly. These "off-the-shelf" treatments offer immediate availability compared to CAR-T's manufacturing delay. Glofitamab, epcoritamab, and mosunetuzumab are among bispecific antibodies in advanced testing for various lymphoma subtypes. Next-generation CAR-T approaches addressing current limitations—including longer-lasting cells, "armored" CAR-T with additional features to enhance persistence, and allogeneic (donor-derived) CAR-T that doesn't require manufacturing from each patient—are in trials. Novel antibody-drug conjugates linking tumor-targeting antibodies with chemotherapy payloads are being tested for multiple lymphoma types, concentrating treatment at cancer sites while reducing systemic toxicity. Targeted therapies for specific genetic subtypes are advancing, including inhibitors targeting PI3K, SYK, and other signaling pathways driving lymphoma growth. New combinations pairing checkpoint inhibitors with other immunotherapies or targeted drugs are in trials, particularly for Hodgkin lymphoma and certain NHL subtypes. Oral chemotherapy formulations and extended-release versions of existing drugs aim to reduce treatment burden and hospital time. BTK inhibitors newer than ibrutinib with improved safety profiles are in advanced testing across multiple lymphoma types.

Universal CAR-T cells that can be manufactured once and used for multiple patients (rather than custom-made for each person) are being developed to eliminate manufacturing delays and potentially reduce costs, with some already in early human trials. CRISPR gene editing is being explored to create more powerful CAR-T cells that resist exhaustion, overcome tumor defense mechanisms, and target multiple markers simultaneously. Scientists are identifying new targets on lymphoma cells beyond CD20 and CD19, developing therapies to attack them through various mechanisms. Researchers are investigating the tumor microenvironment—the surrounding immune cells, blood vessels, and chemical signals that protect lymphoma from attack—to find drugs that disrupt this protective niche. Bispecific antibodies targeting novel combinations of markers are in development, along with trispecific antibodies that bind three different targets simultaneously. Artificial intelligence is analyzing genetic and clinical data to predict which patients will respond to specific treatments and identify new drug targets from massive datasets. Scientists are developing therapeutic cancer vaccines to stimulate immune responses against lymphoma-specific mutations. Researchers are exploring whether gut bacteria influence treatment response and whether modifying the microbiome could enhance immunotherapy effectiveness. Novel approaches to prevent CAR-T side effects while maintaining anti-lymphoma activity are under investigation, including drugs that dampen excessive immune activation. Scientists are working on in vivo CAR-T approaches that would genetically modify T cells directly inside the body rather than requiring extraction and laboratory engineering. Liquid biopsy technologies detecting lymphoma DNA in blood are being refined for earlier relapse detection, treatment monitoring, and possibly screening high-risk individuals. Drugs targeting lymphoma metabolism and epigenetic therapies that alter how genes are turned on or off without changing DNA are in development.